



## Edenbridge sale of Yargesa to Piramal

### Torreya advised Edenbridge on the transaction

Parsippany, NJ USA and Mumbai, India, July 2, 2018

Edenbridge Pharmaceuticals, LLC, a New Jersey based specialty pharmaceutical company, sold its European product Yargesa (miglustat) capsules to Piramal Critical Care, a unit of the India based Piramal Group conglomerate, in a structured transaction. Yargesa was the first European Union-wide generic of Actelion's Zavesca® approved through the centralized procedure and is an oral capsule indicated for the treatment of adult patients with mild to moderate type 1 Gaucher disease.

The transaction enables Edenbridge to monetize a unique European asset and partner with a leading specialty pharmaceutical organization to market Yargesa in the European Union.

Torreya served as financial advisor to Edenbridge on this transaction. The transaction reinforces Torreya's strength and leadership position as an advisor in the generics sector. Torreya has advised on over 36 strategic and financing transactions in the life sciences industry in the last 18 months.

#### ABOUT EDENBRIDGE PHARMACEUTICALS, LLC:

For more information about Edenbridge, please see: [www.edenbridgepharma.com](http://www.edenbridgepharma.com)

#### ABOUT PIRAMAL ENTERPRISES LIMITED:

For more information about Piramal, please see: [www.piramal.com](http://www.piramal.com)



### Torreya Contact

**ALLEN LEFKOWITZ**

Managing Director | New York Office

[allen.lefkowitz@torreya.com](mailto:allen.lefkowitz@torreya.com) | 212.257.5823 | [torreya.com](http://torreya.com)

Torreya is a global advisory firm serving the life sciences industry. Please visit [torreya.com](http://torreya.com) for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.